Regulatory Approval and Asset Acquisition Completed

Global pharmaceutical company Hikma Pharmaceuticals has successfully launched TYZAVAN, a key portfolio product acquired from Xellia Pharmaceuticals, in the U.S. market. This product is a ready-to-infuse vancomycin injectable solution approved by the U.S. Food and Drug Administration (FDA) under NDA 211962. Vancomycin was initially granted final marketing authorization by the FDA on February 15, 2019. Hikma fully acquired ownership of the product following the completion of a major asset transfer agreement with Xellia in September 2024 and began distributing TYZAVAN under its brand name nationwide starting in October 2025. This move allows Hikma to diversify its injectable portfolio in the hospital market, demonstrate regulatory stability, and strengthen its market position.

Mechanism of Action and Clinical Convenience of TYZAVAN

The active ingredient in TYZAVAN, vancomycin, is a representative glycopeptide antibiotic that inhibits the synthesis of cell walls in Gram-positive bacteria. It strongly binds to the terminal D-Ala-D-Ala target molecules in peptidoglycan precursors, thereby sterically hindering cross-linking of the bacterial cell wall. Notably, TYZAVAN is a Ready-to-Infuse formulation, unlike traditional powder injectables, which eliminates the need for complex preparation steps such as sterile compounding, thawing, or dilution at the clinical site. This allows for immediate administration to patients, reducing medication preparation time and effectively preventing compounding errors and cross-contamination risks in critical emergency situations such as septicemia or infective endocarditis.

Financial Terms and Synergies of the Strategic Transaction

The total transaction value for Hikma to acquire Xellia's finished dosage form (FDF) business in the U.S. and its manufacturing facility in Cleveland reached up to USD 185 million. The deal structure included an upfront cash payment of USD 135 million at the time of contract completion and a contingent USD 50 million tied to regulatory approvals and commercial sales milestones. Hikma has also absorbed the R&D center in Zagreb, Croatia, through this transaction, successfully verticalizing its development capabilities. This is expected to accelerate cost reduction for antibiotics and the establishment of large-scale production systems, contributing to long-term improvements in gross margin.

Market Competition and Future Commercial Outlook

The global vancomycin market is projected to exceed USD 1.33 billion in 2025 and is expected to maintain a robust annual growth rate (CAGR) of approximately 5.2% over the next few years due to the increasing frequency of methicillin-resistant Staphylococcus aureus (MRSA) infections in hospitals. Currently, the market is highly competitive, with several pharmaceutical companies, including Baxter, supplying ready-to-infuse liquid products. However, Hikma is pursuing a strategy to rapidly expand TYZAVAN's market share by leveraging its strong partnerships and large distribution networks in the U.S. hospital sector. As U.S. hospitals actively adopt pre-prepared injectables to address staffing shortages and stricter infection control standards, TYZAVAN is expected to demonstrate high commercial flexibility.